Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2025 (Event Date)
Reporting Period: Immediate event reporting regarding a capital raise and listing compliance status.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $5.2 million received from the public offering (after underwriting discounts and estimated expenses).
- Offering Structure:
- 1,340,921 shares of Common Stock at $0.30 per share.
- 17,825,746 Pre-Funded Warrants at $0.299 per warrant (exercise price $0.001).
- Use of Proceeds:
- $2.8 million allocated to Theradex Systems, Inc. for Phase II clinical trials of Ropidoxuridine.
- Up to $2.0 million designated for marketing and advertising services.
- Remaining funds for working capital and general corporate purposes.
- Liquidity Status: The filing does not provide total cash balances or debt figures prior to the offering, only the net proceeds from this specific transaction.
Material Changes and Listing Compliance
The Company previously received notice from Nasdaq on September 10, 2024, regarding non-compliance with the minimum stockholders' equity requirement of $2,500,000 (Rule 5550(b)(1)).
- Compliance Plan: The Company submitted a plan to regain compliance, accepted by Nasdaq on November 26, 2024.
- Current Status: Following the closing of the offering on March 13, 2025, and the receipt of $5.2 million in net proceeds, the Company believes it has met the Minimum Equity Requirement.
- Next Step: Compliance must be demonstrated in the Quarterly Report on Form 10-Q for the period ended March 31, 2025. Failure to evidence compliance at that time may result in delisting.
Outlook, Risks, and Management Commentary
- Clinical Focus: Management intends to fund the Phase II clinical trial for its lead product candidate, Ropidoxuridine (a radiation sensitizer).
- Marketing Strategy: The Company plans to engage an additional IR/PR firm to bolster outreach, utilizing up to $2.0 million of the new capital.
- Risks:
- Delisting Risk: Continued listing on Nasdaq is contingent upon demonstrating equity compliance in the upcoming Q1 2025 Form 10-Q.
- Warrant Restrictions: Pre-Funded Warrants are subject to beneficial ownership limitations (4.99% cap, extendable to 9.99% with notice).
Investor Verification Checklist
- Verify the final stockholders' equity figure in the upcoming Form 10-Q for the period ended March 31, 2025, to confirm Nasdaq compliance.
- Monitor the progress and data readouts of the Phase II clinical trial for Ropidoxuridine funded by the $2.8 million CRO payment.
- Review the dilution impact of the 17.8 million Pre-Funded Warrants upon exercise.
- Confirm the engagement of the additional marketing/IR firm and the allocation of the $2.0 million marketing budget.